SCHEMBL165415

SCHEMBL165415

CCCCCCCC(O)(CC)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 8/20 0.45
GGPS1 O95749 5/20 0.45
CES2 O00748 1/20 0.44
GAA P10253 1/20 0.44
PPARG P37231 3/20 0.43
PPARD Q03181 3/20 0.43
PPARA Q07869 3/20 0.43
TSHR P16473 2/20 0.43
GPR84 Q9NQS5 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
TLR2 O60603 1/20 0.43
MEN1 O00255 1/20 0.43
ESR1 P03372 1/20 0.43
FABP4 P15090 1/20 0.43
ALOX15 P16050 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8380652 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL27492278 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL8376640 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL3294519 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL8376531 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL9633625 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL8377848 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL380519 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL3918719 1.00 FDPS (0.45) FDPSGGPS1CES2GAAPPARG
SCHEMBL380743 0.98 GAA (0.45) FDPSGGPS1CES2GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282807-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS AMPHISTAR (BE) 2025-09-11 US claimed
EP-3692981-B1 TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS CHEM CURE ASS LLC (US) 2022-05-04 EP claimed
EP-3305299-B1 METHOD AND COMPOSITIONS FOR TREATING PSORIASIS ANAPLASI PHARMACEUTICALS LLC (US) 2020-04-29 EP claimed
EP-2363112-B1 OSMOTIC DELIVERY SYSTEMS AND PISTON ASSEMBLIES INTARCIA THERAPEUTICS INC (US) 2018-10-10 EP claimed
EP-2906199-B1 METHOD AND COMPOSITIONS FOR TREATING PSORIASIS ANAPLASI PHARMACEUTICALS LLC (US) 2018-01-03 EP claimed
EP-2285212-B1 NOVEL PYRIPROXYFEN COMPOSITIONS SUMITOMO CHEMICAL CO (JP) 2016-02-17 EP claimed
EP-1814652-B1 SURFACTANT SYSTEM METHOD SURFACE ACTIVE SOLUTIONS HOLDINGS LTD (GB) 2015-06-17 EP claimed
EP-0768817-B1 EMULSIFIABLE CONCENTRATES CONTAINING ONE OR MORE PESTICIDES HOECHST SCHERING AGREVO SA (FR) 2000-03-15 EP claimed
US-20250282807-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS AMPHISTAR (BE) 2025-09-11 US disclosed
EP-4313350-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS AMPHISTAR BV (BE) 2024-02-07 EP disclosed
WO-2022207086-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS BIO BASE EUROPE PILOT PLANT VZW (BE) 2022-10-06 WO disclosed
EP-3300795-B1 A PROCESS FOR OBTAINING MICROCAPSULES SIPCAM OXON S P A (IT) 2021-06-30 EP disclosed
US-20200102255-A1 NEW METHOD FOR FERTILIZING AGRICULTURAL SOIL BASF CORPORATION 2020-04-02 US disclosed
EP-2718411-B1 SOPHOROLACTONE COMPOSITIONS AND USES THEREOF ECOVER CO ORDINATION CENTER N V (BE) 2019-09-11 EP disclosed
WO-2011029561-A2 PESTICIDE PREPARATIONS CLARIANT INTERNATIONAL LTD (CH) 2011-03-17 WO disclosed
WO-2011012493-A2 PESTICIDAL SUSPO-EMULSION COMPOSITIONS BASF SE (DE) 2011-02-03 WO disclosed
WO-2010069848-A2 AGROCHEMICAL FORMULATIONS CONTAINING PYRROLIDONE ALKYLENE OXIDES BASF SE (DE) 2010-06-24 WO disclosed
EP-2152843-A2 MIXTURE COMPRISING AN ALKYL POLYGLUCOSIDE, A COSURFACTANT AND A POLYMER ADDITIVE Bernd Schwegmann Gmbh&co. Kg (DE) 2010-02-17 EP disclosed
WO-2008132202-A2 MIXTURE COMPRISING AN ALKYL POLYGLUCOSIDE, A COSURFACTANT AND A POLYMER ADDITIVE BERND SCHWEGMANN GMBH & CO. KG (DE) 2008-11-06 WO disclosed
US-6468995-B1 ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282807-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS MGLL, LIPA, LIPC FDPS 660/4885GGPS1 104/4885CES2 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.